Eli Lilly Presents Long-Term Omvoh Data Showing Sustained Remission in Ulcerative Colitis

Eli Lilly today announced long-term data from the LUCENT clinical program evaluating mirikizumab (Omvoh) in patients with moderately to severely active ulcerative colitis. At 2 years, 58% of patients maintained clinical remission and 51% maintained endoscopic remission. The long-term safety profile was consistent with previous observations, with no new safety signals identified. These data demonstrate the sustained efficacy and favorable long-term safety of Omvoh and support its use as a long-term treatment option for ulcerative colitis patients.